Patents by Inventor Django Sussman

Django Sussman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200062857
    Abstract: The present invention provides variant target binding agents and methods relating to the use of such binding agents for the prophylaxis or treatment of cancers and immunological disorders. The variant target binding agent is conjugated to a therapeutic agent that exerts a cytotoxic, cytostatic, or immunomodulatory effect on target cells.
    Type: Application
    Filed: July 29, 2019
    Publication date: February 27, 2020
    Applicant: Seattle Genetics, Inc.
    Inventors: Paul Carter, Django Sussman
  • Publication number: 20200031938
    Abstract: The invention provides antibodies that specifically bind to integrin ?v?6. The antibodies are useful for treatment and diagnoses of various cancers as well as detecting ?v?6.
    Type: Application
    Filed: September 30, 2019
    Publication date: January 30, 2020
    Applicant: SEATTLE GENETICS, INC.
    Inventors: Maureen Ryan, Django Sussman
  • Publication number: 20200002431
    Abstract: The invention provides humanized antibodies that specifically bind to BCMA. The antibodies are useful for treatment and diagnoses of various cancers and immune disorders as well as detecting BCMA.
    Type: Application
    Filed: May 14, 2019
    Publication date: January 2, 2020
    Applicant: SEATTLE GENETICS, INC.
    Inventors: Django Sussman, Maureen Ryan, Lori Westendorf, Michael Feldhaus
  • Publication number: 20190381171
    Abstract: Disclosed herein are methods of enhancing antibody-dependent cell cytotoxicity (ADCC) in a subject comprising administering to a subject in need thereof a therapeutically effective amount of an anti-BCMA antibody and an effective amount of T lymphocytes and/or NK cells expressing an antibody-coupled T-cell receptor (ACTR) construct, which may comprises an extracellular domain with affinity and specific for the Fc portion of an immunoglobulin molecule (Ig); a transmembrane domain; optionally one or more of co-stimulatory domains, and a cytoplasmic signaling domain comprising an immunoreceptor tyrosine-based activation motif (ITAM).
    Type: Application
    Filed: February 16, 2018
    Publication date: December 19, 2019
    Applicant: UNUM THERAPEUTICS INC.
    Inventors: Heather HUET, Seth ETTENBERG, Django SUSSMAN, Tooba CHEEMA, Taylor HICKMAN, Katie O'CALLAGHAN, Maureen RYAN
  • Patent number: 10443035
    Abstract: The invention provides methods and compositions for preparing antibodies and antibody derivatives with reduced core fucosylation.
    Type: Grant
    Filed: October 10, 2017
    Date of Patent: October 15, 2019
    Assignee: Seattle Genetics, Inc.
    Inventors: Stephen C. Alley, Scott C. Jeffrey, Django Sussman, Dennis R. Benjamin, Brian Toki, Patrick J. Burke
  • Publication number: 20190276796
    Abstract: The invention provides methods and compositions for preparing antibodies and antibody derivatives with reduced core fucosylation.
    Type: Application
    Filed: May 16, 2019
    Publication date: September 12, 2019
    Inventors: Stephen C. ALLEY, Scott C. JEFFREY, Django SUSSMAN, Dennis R. BENJAMIN, Brian TOKI, Patrick J. BURKE
  • Patent number: 10407505
    Abstract: The present invention provides variant target binding agents and methods relating to the use of such binding agents for the prophylaxis or treatment of cancers and immunological disorders. The variant target binding agent is conjugated to a therapeutic agent that exerts a cytotoxic, cytostatic, or immunomodulatory effect on target cells.
    Type: Grant
    Filed: June 22, 2016
    Date of Patent: September 10, 2019
    Assignee: Seattle Genetics, Inc.
    Inventors: Paul Carter, Django Sussman
  • Publication number: 20190194338
    Abstract: The invention provides humanized antibodies that specifically bind to BCMA. The antibodies are useful for treatment and diagnoses of various cancers and immune disorders as well as detecting BCMA.
    Type: Application
    Filed: February 16, 2017
    Publication date: June 27, 2019
    Applicant: SEATTLE GENETICS, INC.
    Inventors: Django Sussman, Maureen Ryan, Lori Westendorf, Michael Feldhaus
  • Publication number: 20190085091
    Abstract: The invention provides methods of treating a subject having or at risk of cancer by administering a LIV-1 antibody drug conjugate and a chemotherapeutic.
    Type: Application
    Filed: March 15, 2017
    Publication date: March 21, 2019
    Applicant: SEATTLE GENETICS, INC.
    Inventors: Django Sussman, Fu Li, Ana Kostic
  • Publication number: 20190023801
    Abstract: The invention provides humanized antibodies that specifically bind to BCMA. The antibodies are useful for treatment and diagnoses of various cancers and immune disorders as well as detecting BCMA.
    Type: Application
    Filed: October 3, 2018
    Publication date: January 24, 2019
    Applicant: SEATTLE GENETICS, INC.
    Inventors: Django Sussman, Maureen Ryan, Lori Westendorf, Michael Feldhaus
  • Publication number: 20180169261
    Abstract: The invention provides murine, chimeric, and humanized antibodies that specifically bind to CD123 and conjugates thereof.
    Type: Application
    Filed: June 9, 2016
    Publication date: June 21, 2018
    Applicant: SEATTLE GENETICS, INC.
    Inventors: May Kung Sutherland, Lori Westendorf, Django Sussman
  • Publication number: 20180169257
    Abstract: Disclosed are antibodies, including antibody drug conjugates, that specifically bind to NTB-A. Also disclosed are methods for using the anti-NTB-A antibodies to detect or modulate activity of (e.g., inhibit proliferation of) an NTB-A-expressing cell, as well as for diagnoses or treatment of diseases or disorders (e.g., cancer) associated with NTB-A-expressing cells, such as multiple myeloma, non-Hodgkin lymphoma and acute myeloid leukemia.
    Type: Application
    Filed: June 30, 2016
    Publication date: June 21, 2018
    Applicant: SEATTLE GENETICS, INC.
    Inventors: Timothy Lewis, Lori Westendorf, Django Sussman, Che-Leung Law
  • Publication number: 20180155677
    Abstract: The invention provides methods and compositions for preparing antibodies and antibody derivatives with reduced core fucosylation.
    Type: Application
    Filed: October 10, 2017
    Publication date: June 7, 2018
    Inventors: Stephen C. ALLEY, Scott C. Jeffrey, Django SUSSMAN, Dennis R. BENJAMIN, Brian TOKI, Patrick J. BURKE
  • Publication number: 20180079810
    Abstract: The invention provides humanized antibodies that specifically bind to LIV-1. The antibodies are useful for treatment and diagnoses of various cancers as well as detecting LIV-1.
    Type: Application
    Filed: August 31, 2017
    Publication date: March 22, 2018
    Inventors: Maria Leia Smith, Django Sussman, William Arthur, Albina Nesterova
  • Patent number: 9816069
    Abstract: The invention provides methods and compositions for preparing antibodies and antibody derivatives with reduced core fucosylation.
    Type: Grant
    Filed: February 26, 2015
    Date of Patent: November 14, 2017
    Assignee: SEATTLE GENETICS, INC.
    Inventors: Stephen C. Alley, Scott C. Jeffrey, Django Sussman, Dennis R. Benjamin, Brian Toki, Patrick J. Burke
  • Patent number: 9783608
    Abstract: The invention provides humanized antibodies that specifically bind to LIV-1. The antibodies are useful for treatment and diagnoses of various cancers as well as detecting LIV-1.
    Type: Grant
    Filed: November 20, 2015
    Date of Patent: October 10, 2017
    Assignee: SEATTLE GENETICS, INC.
    Inventors: Maria Leia Smith, Django Sussman, William Arthur, Albina Nesterova
  • Publication number: 20170233484
    Abstract: The invention provides humanized antibodies that specifically bind to BCMA. The antibodies are useful for treatment and diagnoses of various cancers and immune disorders as well as detecting BCMA.
    Type: Application
    Filed: February 16, 2017
    Publication date: August 17, 2017
    Applicant: SEATTLE GENETICS, INC.
    Inventors: Django Sussman, Maureen Ryan, Lori Westendorf, Michael Feldhaus
  • Publication number: 20170204180
    Abstract: The invention provides murine, chimeric, and humanized antibodies that specifically hind to CD33. The antibodies are useful for treatment and diagnoses of various cancers as well as detecting CD33.
    Type: Application
    Filed: January 20, 2017
    Publication date: July 20, 2017
    Inventors: May Kung Sutherland, Maureen Ryan, Django Sussman, Patrick Burke, Scott Jeffrey
  • Patent number: 9587019
    Abstract: The invention provides murine, chimeric, and humanized antibodies that specifically bind to CD33. The antibodies are useful for treatment and diagnoses of various cancers as well as detecting CD33.
    Type: Grant
    Filed: May 15, 2013
    Date of Patent: March 7, 2017
    Assignee: SEATTLE GENETICS, INC.
    Inventors: May Kung Sutherland, Maureen Ryan, Django Sussman, Patrick Burke, Scott Jeffrey
  • Publication number: 20160367697
    Abstract: The present invention provides variant target binding agents and methods relating to the use of such binding agents for the prophylaxis or treatment of cancers and immunological disorders. The variant target binding agent is conjugated to a therapeutic agent that exerts a cytotoxic, cytostatic, or immunomodulatory effect on target cells.
    Type: Application
    Filed: June 22, 2016
    Publication date: December 22, 2016
    Inventors: Paul Carter, Django Sussman